- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Customers Sue UnitedHealth for Overcharging on Drugs
What we're reading, October, 6, 2016: UnitedHealth is sued for allegedly overcharging on prescription drugs; the Obama administration could point consumers to remaining insurance options as insurers leave the Affordable Care Act exchanges; and human life spans may have it a ceiling.
UnitedHealth customers are suing the company for alleging overcharging on prescription drugs. According to Bloomberg, customers were paying copayments that were far more than the cost of the actual drugs. The lawsuit is seeking class-action status on behalf of tens of thousands of customers. This is not the first time UnitedHealth has been sued for overcharging for prescription drugs.
The federal government is concerned that health insurers leaving the Affordable Care Act marketplaces may cause customers to flee, as well. As a result, the Obama administration is considering steering customers affected by an insurer leaving to remaining options, reported the Associated Press. Insurers are concerned the move may cause confusion among consumers, but consumer advocates believe the plan will help people remained covered.
Human life spans have been increasing, but there may be an upper limit. Research published in Nature finds that human life spans may hit the ceiling at 115 years, according to NPR. While the maximum life span could be as high as 125 years, the chances of anyone reaching that age is low. The only way human life span may increase is if scientists can determine a way to fight the cause of aging instead of diseases.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
